GlassScriptPhysician profile
Joanne C Siu-Post
NPI 1184720823
$4,182.28
in general payments reported to CMS, 2019-2025
28 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $222 · 2021: $461 · 2022: $663 · 2023: $823 · 2024: $692 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.78 |
| Education | $193.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.41 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $508.26 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $475.86 | 2021-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $362.21 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $247.16 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $192.19 | 2022-2023 | Benlysta |
| Scpharmaceuticals INC. | $190.04 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.08 | 2021-2025 | |
| Travere Therapeutics, INC. | $160.89 | 2022-2025 | Filspari |
| Akebia Therapeutics INC | $142.27 | 2019-2024 | Auryxia, Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.41 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $139.10 | 2021-2025 | |
| Ardelyx, INC. | $120.67 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $112.80 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $111.51 | 2019-2023 | Veltassa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $105.68 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $92.26 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $84.52 | 2024-2025 | Velphoro, Velphoro |
| Baxter Healthcare | $43.24 | 2022-2023 | Renal - Pd |
| Calliditas Therapeutics US INC. | $40.80 | 2023 | Tarpeyo |
| Novo Nordisk INC | $38.83 | 2023-2024 | Ozempic, Rybelsus |
| Cormedix INC. | $37.15 | 2024 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.17 | 2025 | |
| Alexion Pharmaceuticals, INC. | $28.17 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $25.36 | 2023 | Givlaari |
| Seqirus USA INC | $19.86 | 2025 | Fluad, Flucelvax |
| Mannkind Corporation | $19.81 | 2025 | |
| Daiichi Sankyo INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Siu-Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.